Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution

Medical Physics

Volumn 32, Issue 1, 2005, Pages 200-208

  Bao, Ande ^a   Zhao, Xia ^a   Phillips, William T ^a   Woolley, F Ross ^a   Otto, Randal A ^a   Goins, Beth ^a   Hevezi, James M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Dose nonuniformity; Iodine 131; Kernel; Radionuclide dosimetry; Rhenium 186; Rhenium 188; Tumor; Yttrium 90

Indexed keywords

CONTROLLED DRUG DELIVERY; DISTRIBUTION FUNCTIONS; FAST FOURIER TRANSFORMS; FREQUENCY DOMAIN ANALYSIS; RADIOISOTOPES; TARGETED DRUG DELIVERY;

ABSORBED DOSE DISTRIBUTION; INTRATUMORAL DRUG DELIVERIES; IODINE-131; KERNEL; NONUNIFORMITY; THERAPEUTIC RADIONUCLIDES; THREE-DIMENSIONAL (3D) CONVOLUTION; YTTRIUM-90;

TUMORS;

ANTINEOPLASTIC AGENT; IODINE 131; RHENIUM 186; RHENIUM 188; YTTRIUM 90;

ARTICLE; DOSIMETRY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; FOURIER TRANSFORMATION; HEMATOLOGIC MALIGNANCY; ISOTOPE LABELING; MATHEMATICAL ANALYSIS; METASTASIS; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; SIMULATION; SOLID TUMOR;

EID: 12844288857     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.1833151     Document Type: Article

References (31)

1. J. Carlsson, E. F. Aronsson, S.-O. Hietala, T. Stigbrand, and J. Tennvall, "Tumor therapy with radionuclides: Assessment of progress and problems," Radiother. Oncol. 66, 107-117 (2003).
2. D. M. Goldenberg, "Targeted therapy of cancer with radiolabeled antibodies," J. Nucl. Med. 43, 693-713 (2002).
3. D. M. Goldenberg, "Advancing role of radiolabeled antibodies in the therapy of cancer," Cancer Immunol. Immunother. 52, 281-296 (2003).
4. D. M. Goldenberg, "The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: The coming of age of radioimmunotherapy, " Crit. Rev. Oncol. Hematol. 39, 195-201 (2001).
5. C. Emmanouilides, "Radioimmunotherapy for non-Hodgkin's lymphoma," Semin. Oncol. 30, 531-544 (2003).
6. 90Y-DOTATOC in association with amino acid infusion: A phase I study," Eur. J. Nucl. Med. 30, 207-216 (2003).
7. R. K. Jain and L. T. Baxter, "Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumours: Significance of elevated interstitial pressure," Cancer Res. 48, 7022-7032 (1988).
8. R. K. Jain, "Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors," Cancer Res. 50(Suppl.), 814s-819s (1990).
9. T. M. Behr, R. D. Blumenthal, S. Memtosoudis, R. M. Sharkey, S. Gratz, W. Becker, and D. M. Goldenberg, "Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments," Clin. Cancer Res. 6, 4900-4907 (2000).
10. J. L. J. Dearling, A. A. Flynn, J. Sutcliffe-Goulden, I. A. Petrie, R. Boden, A. J. Green, G. M. Boxer, R. H. J. Begent, and R. B. Pedley, "Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts," J. Nucl. Med. 45, 101-107 (2004).
11. 64Cu-ATSM: A comparison study with FDG," Nucl. Med. Biol. 30, 529-534 (2003).
12. A. E. Nahum, "Microdosimetry and radiocurability: modeling targeted therapy with β-emitters," Phys. Med. Biol. 41, 1957-1972 (1996).
13. 186Re as a function of tumor size, uptake, and intracellular distribution," Int. J. Radiat. Oncol., Biol., Phys. 36, 197-204 (1996).
14. M. G. Steffens, O. C. Boerman, W. J. G. Oyen, P. H. M. Kniest, J. A. Witjes, G. O. N. Oosterhof, G. J. L. H. van Leenders, F. M. J. Debruyne, F. H. M. Corstens, and E. Oosterwijk, "Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy," Cancer Res. 59, 1615-1619 (1999).
15. C. S. Kwok, W. V. Prestwich, and B. C. Wilson, "Calculation of radiation doses for nonuniformly distributed β and γ radionuclides in soft tissues," Med. Phys. 12, 405-412 (1985).
16. R. W. Howell, R. V. Rao, and K. S. R. Sastry, "Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distribution in solid tumors," Med. Phys. 16, 66-74 (1989).
17. D. A. Weber, K. F. Eckerman, L. T. Dillman, and J. C. Ryman, "MIRD: Radionuclide Data and Decay Schemes," Society of Nuclear Medicine, Inc. Reston, VA, pp. 228-229, 328-331, and 159 (1989).
18. J. Zweit, "Radionuclides and carrier molecules for therapy," Phys. Med. Biol. 41, 1905-1914 (1996).
19. H. B. Giap, D. J. Macey, J. E. Bayouth, and A. L. Boyer, "Validation of a dose-point kernel convolution technique for internal dosimetry," Phys. Med. Biol. 40, 365-381 (1995).
20. 11C]M100907," Synapse 38, 421-431 (2000).
21. W. V. Prestwich, J. Nunes, and C. S. Kwok, "Beta dose point kernels for radionuclides of potential use in radioimmunotherapy," J. Nucl. Med. 30, 1036-1046 (1989).
22. D. J. Simpkin and T. R. Mackie, "EGS4 Monte Carlo determination of the beta dose kernel in water," Med. Phys. 17, 179-186 (1990).
23. E. E. Furhang, G. Sgouros, and C.-S. Chui, "Radionuclide photon dose kernels for internal emitter dosimetry," Med. Phys. 23, 759-764 (1996).
24. P. R. Almond, P. J. Biggs, B. M. Coursey, W. F. Hanson, M. S. Huq, R. Nath, and D. W. Rogers, "AAPM's TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams," Med. Phys. 26, 1847-1870 (1999).
25. 64Cu-labeled RGD peptide," Bioconjugate Chem. 15, 41-49 (2004).
26. R. W. Howell, S. M. Goddu, and D. V. Rao, "Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy," Med. Phys. 25, 37-42 (1998).
27. J-P. Massin, J-C. Savoie, H. Garnier, G. Guiraudon, F. A. Leger, and F. Bacourt, "Pulmonary metastases in differentiated thyroid carcinoma-Study of 58 cases with implications for the primary tumor treatment," Cancer 53, 982-992 (1984).
28. J. C. Sisson, D. A. Jamadar, E. A. Kazerooni, T. J. Giordano, J. E. Care, and S. A. Spaulding, "Treatment of micronodular lung metastases of papillary thyroid cancer: Are the tumors too small for effective irradiation from radioiodine?," Thyroid 8, 215-221 (1998).
29. C. Janicki, D. M. Duggan, and D. A. Rahdert, "A dose-point-kernel model for a low energy gamma-emitting stent in a heterogeneous medium," Med. Phys. 28, 1397-1405 (2001).
30. C. Janicki and J. Seuntjens, "Accurate determination of dose-point-kernel functions close to the origin using Monte Carlo simulations," Med. Phys. 31, 814-818 (2004).
31. A. Liu, L. E. Williams, J, Y. Wong, and A. A. Raubitschek, "Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry," Nucl. Med. Biol. 25, 423-433 (1998).